[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tonsillitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tonsillitis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,46,78,113,141,170,204,230,262,289],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100638307","transoral-ultrasound-versus-no-transoral-ultrasound-in-diagnostic-workup-of-peritonsillar-abscess-100638307",false,"NCT07577232","Transoral Ultrasound Versus no Transoral Ultrasound in Diagnostic Workup of Peritonsillar Abscess","Transoral Ultrasound Versus no Transoral Ultrasound in Diagnostic Workup of Peritonsillar Abscess - Proposal for a Multicenter Cluster Randomized Trial","Inclusion Criteria:\n\n* Patients referred to the ENT outpatient clinic with a suspected PTA.\n* 18 years of age or older.\n\nExclusion Criteria:\n\n* Unable to understand the verbal information, participating in research.\n* Prior surgical interventions (needle aspiration, surgery, incision) during the course of the disease.\n* Compromised airways, needing acute airway management.","ALL","18 Years",{"count":19,"type":20},368,"ESTIMATED","INTERVENTIONAL",[23],"NA","Peritonsillar abscess (PTA) is a collection of pus between the palatine tonsil and the constrictor muscle. PTA is detected by recognizing characteristics during clinical examination: redness, pain, malaise, trismus, and unilateral peritonsillar swelling. Clinical assessment, including inspection and palpation, is the traditional diagnostic method for patients suspected of having PTA. If PTA is suspected, aspiration with a large-gauge needle or incision is performed to drain the abscess . It can be challenging to distinguish PTA and peritonsillar cellulitis (PTC) based on clinical examination alone. Due to the increased availability of point-of-care ultrasound, it is a part of the diagnostic workup of PTA. Several studies have shown that transoral US can improve the diagnostic accuracy of patients with a suspected PTA. However, no large multicenter study has evaluated whether one of these methods is superior to the other. It is therefore very clinician-dependent whether the patient will have a transoral US performed or not. The investigators hypothesize that transoral US will increase the diagnostic accuracy of PTA compared to solely clinical examination, which is a visual and palpatory assessment. This will result in fewer unnecessary aspiration attempts and overlooked PTAs. Additionally, the investigators wish to investigate the number of aspirations of transoral US-guided needle aspirations compared to aspirations without ultrasound.\n\nMethods This is a cluster randomized study. Patients with suspected PTA will be randomized 1:1 to groups A and B. The cluster randomization will happen weekly using an online randomization tool.\n\nParticipants are patients refeered to the outpatient clinic on suspicion of a peritonsillar absces.\n\nThe primary outcome is the diagnostic accuracy\n\nThe investigators aim to determine whether transoral US is a standard part of the clinical examination by comparing clinical examinations with and without US.",[26,27,28],"Peritonsillar Abscess","Peritonsillar Cellulitis","Tonsillitis",[30,31,32],"Transoral ultrasound","peritonsillar abscess","Peritonsillar cellulitis","RECRUITING","2026-05-05",{"date":36,"type":37},"2026-05-11","ACTUAL",{"date":39,"type":37},"2025-06-09",{"date":41,"type":20},"2026-07-01",{"name":43,"class":44},"Rigshospitalet, Denmark","OTHER",3,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":63,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":45},"100489687","evaluating-the-genetics-and-immunology-of-periodic-fever-aphthous-stomatitis-pharyngitis-and-cervical-adenitis-pfapa-syndrome-and-other-tonsil-disorders-100489687","NCT05656365","Evaluating the Genetics and Immunology of Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome and Other Tonsil Disorders","* INCLUSION CRITERIA:\n\nParticipants must meet all the following inclusion criteria to be eligible for this study:\n\n1. Aged \\>=1 month. To be seen at the NIH CC, participants must be \\>=3 years of age.\n2. Diagnosed with PFAPA or another tonsil disorder, or has symptoms consistent with these conditions, as determined by the investigator.\n3. Able to provide informed consent (for ages \\>=18 years) or has a parent or guardian who can provide informed consent on their behalf (for ages \\\u003C18 years).\n4. Willing to allow specimens and data to be stored for future research.\n5. Willing to allow genetic testing on their biospecimens.\n\nEXCLUSION CRITERIA:\n\nAn individual who has any condition that, in the judgment of the investigator, may put them at undue risk or make them unsuitable for participation in the study will be excluded.","1 Month","99 Years",{"count":55,"type":20},1500,"OBSERVATIONAL","Background:\n\nPeriodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) is the most common periodic fever syndrome of childhood. Symptoms can include swelling of the glands in the throat, mouth ulcers, and tonsillitis. Removal of the tonsils can stop the periodic flareups. But researchers do not know how PFAPA develops. In this natural history study, researchers will collect specimens and data from people with PFAPA to see what they might have in common.\n\nObjective:\n\nTo collect blood and other specimens from people with PFAPA to learn more about the illness.\n\nEligibility:\n\nPeople aged 1 month or older with symptoms of PFAPA or another tonsil disorder.\n\nDesign:\n\nParticipants will be screened. Their medical records will be reviewed. Researchers will ask about a family history of PFAPA.\n\nThe following specimens may be collected:\n\nBlood. Blood will be drawn either from a needle inserted into a vein or from a prick in the finger or heel.\n\nMucus and cells. A stick with soft padding on the tip may be rubbed inside the nostrils or mouth.\n\nStool.\n\nSaliva.\n\nTissue samples may be taken if participants are having surgery to remove the tonsils or adenoids. Participants having surgery may also have a nasopharyngeal wash; salt water will be squirted into the back of the throat and then sucked back out with a syringe.\n\nMost participants will provide specimens only once. They can do this in person at the clinic; they can also have their local health providers send specimens to the researchers. Some participants may have optional follow-up visits over 10 years.",[59,60,28,61,62],"Periodic Fever, Aphthous Stomatitis, Pharyngitis, And Cervical Adenitis (Pfapa)","Obstructive Sleep Apnea","Tonsil Disorder","Sleep Disordered Breathing",[64,65,66,28,60,62,67],"Genome-Wide Association Study (Gwas)","Immunology","Autoinflammation","Natural History","2026-04-07",{"date":70,"type":37},"2026-04-08",{"date":72,"type":37},"2023-05-23",{"date":74,"type":20},"2038-12-31",{"name":76,"class":77},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":21,"phases":89,"briefSummary":90,"conditions":91,"keywords":98,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":112},"100483466","lateral-pharyngoplasty-outcomes-in-children-undergoing-tonsillectomy-100483466","NCT05575401","Lateral Pharyngoplasty Outcomes in Children Undergoing Tonsillectomy","Post-operative Outcomes of Tonsillectomy With Lateral Pharyngoplasty Versus Tonsillectomy Alone in Children: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Participants ages 3-17 years of age undergoing tonsillectomy +\u002F- adenoidectomy at Loma Linda University Health\n\nExclusion Criteria:\n\n* Subjects with congenital syndromes and\u002For developmental delay\n* Subjects with cancer\n* Subjects with gastrostomy tube use or dependence\n* Subjects undergoing intracapsular tonsillectomy","3 Years","17 Years",{"count":88,"type":20},160,[23],"The goal of this treatment study is to determine if doing lateral pharyngoplasty with tonsillectomy is better for children than doing tonsillectomy alone. The main questions it aims to answer are:\n\n* Do children experience less pain after surgery when lateral pharyngoplasty is performed with tonsillectomy compared to tonsillectomy alone?\n* Do children eat\u002Fdrink better when lateral pharyngoplasty is performed with tonsillectomy compared to tonsillectomy alone?\n* Is there a lower risk of bleeding after tonsillectomy when lateral pharyngoplasty is performed? Researchers will compare children undergoing tonsillectomy and lateral pharyngoplasty with children undergoing tonsillectomy alone to see if the participants experience less pain, better oral intake, and less bleeding complications after surgery. Parents of participants will be asked to record pain scores and pain medications given, approximate amounts of daily oral intake, and any complications after surgery.",[92,93,94,28,95,96,97],"Sleep-Disordered Breathing","Sleep Apnea Syndromes in Children","Sleep Apnea, Obstructive","Tonsillar Hypertrophy","Tonsil Stone","Tonsil Disease",[99,100,101,102],"Tonsillectomy","Post-tonsillectomy hemorrhage","Post-tonsillectomy complication","Lateral pharyngoplasty","2026-02-19",{"date":105,"type":37},"2026-02-23",{"date":107,"type":37},"2023-05-17",{"date":109,"type":20},"2026-12",{"name":111,"class":44},"Loma Linda University",4,{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":21,"phases":123,"briefSummary":124,"conditions":125,"keywords":126,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":4},"100606513","suprazygomatic-maxillary-nerve-block-in-pediatric-tonsillectomy-100606513","NCT07176533","Suprazygomatic Maxillary Nerve Block in Pediatric Tonsillectomy","Opioid-Free Pediatric Tonsillectomy With Intraoperative Maxillary Nerve Block Via Suprazygomatic Injection (OPTIMaS): A Randomized Controlled Triple-Blinded Trial","Inclusion Criteria:\n\n1. Patients undergoing coblation intracapsular tonsillectomy or adenotonsillectomy for sleep apnoea.\n2. Between 3-9 years old (inclusive).\n3. Patient(s) and guardian(s) can consent to participate in the study.\n4. Legal guardian(s) can read and write in English.\n\nExclusion Criteria:\n\n1. Patient or legal guardian refusal to participate in the study.\n2. Emergency surgery.\n3. Allergies to local anesthetics.\n4. Patients with coagulopathy.\n5. Congenital facial abnormalities including (but not limited to) hemifacial microsomia, maxillary hypoplasia, Treacher-Collins syndrome, and Goldenhar syndrome.\n6. Developmental delay or neurological impairment including (but not limited to) Trisomy 21, cerebral palsy, and autism spectrum disorder.\n7. Previous airway surgery or a known or predicted airway difficulty.","9 Years",{"count":122,"type":20},60,[23],"Tonsillectomies are among the most common surgical procedures performed in pediatric populations, with more than 14,000 procedures performed annually in Ontario, with more than 80% being performed to treat sleep-disordered breathing, including sleep apnea. Despite being a routine procedure, postoperative pain is a prevalent challenge following tonsillectomies, with significant pain lasting 7 to 10 days and peaking within the first 3 days following surgery. Effective pain management is critical not only to enhance patient comfort, but to ensure functional recovery, decrease the risk of post-surgical complications, and reduce the risk of hospital readmissions. The suprazygomatic maxillary nerve block (SZMN block) has become a promising alternative to opioids for the management of post-tonsillectomy pain. The SZMN block numbs the nerves in the facial region that would contribute to feeling pain following tonsillectomy. Although the SZMN block has been successful in adult tonsillectomies and pediatric cleft palate repairs, its success in pediatric tonsillectomies remains under investigation. This randomized controlled trial aims to evaluate the efficacy and safety of the SZMN block in pediatric tonsillectomy and adenotonsillectomy patients, through its role in providing pain management over 14 days following surgery. This study will be conducted at Victoria Hospital, London Health Sciences Centre.",[28],[127,99,128,129,130],"Pain control","Adenotonsillectomy","Suprazygomatic maxillary nerve block","Anesthesia","NOT_YET_RECRUITING","2025-12-05",{"date":134,"type":37},"2025-12-12",{"date":136,"type":20},"2026-01-01",{"date":138,"type":20},"2028-01-01",{"name":140,"class":44},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":149,"sex":16,"minAge":85,"maxAge":86,"enrollmentInfo":150,"targetDuration":4,"studyType":21,"phases":152,"briefSummary":154,"conditions":155,"keywords":158,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":169},"100560414","phase-4-optimization-of-pediatric-tonsillectomy-to-improve-analgesia-100560414","NCT06576830","Optimization of Pediatric Tonsillectomy to IMprove AnaLgesia","Single-Dose Intraoperative Methadone for Pain Management in Pediatric Tonsillectomy: A Randomized Double Blind Clinical Trial","OPTIMAL","Inclusion Criteria:\n\n1. Age \\>= 3 and \\\u003C 18 years\n2. Elective tonsillectomy +\u002F- adenoidectomy\n3. Signed informed consent by parent or legal guardian\n4. Children \\>= 12 years must provide signed written consent, Children \\>= 7 years must provide verbal assent\n5. Negative pregnancy test within 48 hours for post pubescent females\n\nExclusion Criteria:\n\n1. History of chronic kidney or liver disease\n2. Current diagnosis of a chronic pain disorder\n3. Planned admission to the Pediatric Intensive Care Unit (PICU)\n4. Additional procedures under general anesthesia for which opioids would be prescribed",true,{"count":151,"type":20},440,[153],"PHASE4","The purpose of this study is to compare the use of short acting opioids (fentanyl\u002Fhydromorphone) with long acting opioids (methadone) for pain control following tonsillectomy surgery in children and adolescents.",[156,95,28,157,92],"Pain, Postoperative","Pediatric Sleep Apnea",[159,99,160],"Methadone","Opioid","2025-12-01",{"date":132,"type":37},{"date":164,"type":37},"2024-11-21",{"date":166,"type":20},"2029-06-01",{"name":168,"class":44},"Duke University",1,{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":16,"minAge":178,"maxAge":86,"enrollmentInfo":179,"targetDuration":4,"studyType":21,"phases":181,"briefSummary":182,"conditions":183,"keywords":190,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":169},"100600150","perspectives-on-antibiotics-and-tracking-symptoms-in-children-100600150","NCT07093749","Perspectives on Antibiotics and Tracking Symptoms in Children","PATSy Perspectives on Antibiotics and Tracking Symptoms in Children - a Mixed Methods Feasibility Study","PATSy","Inclusion Criteria:\n\n* Between the ages of ≥ 4 years and ≤ 17 years at enrolment.\n* Diagnosed with any of the following at RCH ED: urinary tract infection (UTI), cellulitis, impetigo, pharyngitis, tonsillitis, respiratory tract infections, otitis media.\n* Prescribed oral antibiotics (either immediately or as switch from IV antibiotics after transfer to HITH) as standard of care due to having uncomplicated infection as deemed by their treating doctor.\n* Parent\u002Fguardian provides a signed and dated informed consent form.\n\nExclusion Criteria:\n\n\\- Parent\u002Fguardian does not speak English","4 Years",{"count":180,"type":20},300,[23],"The study will assess families' perspectives and decision-making regarding the duration of oral antibiotic courses prescribed to children (4-17 years) who present with uncomplicated bacterial infections at the Royal Children's Hospital (RCH) Emergency Department (ED). The study will involve (i) children discharged from ED on oral antibiotics and (ii) children transferred to Hospital-in-the-Home (HITH) on IV antibiotics who then switch to oral antibiotics. In addition, the study will assess how feasible and acceptable it is to track children's symptoms via the Garmin Smartwatch and the WeGuide platform (WeGuide is a patient engagement software platform that allows for enrolment, consent, and data collection \\[via questionnaires\u002Fsurveys and from the Garmin Smartwatches\\] through a singular platform).",[184,185,186,187,28,188,189],"Urinary Tract Infection","Cellulitis","Impetigo","Pharyngitis","Respiratory Tract Infections","Otitis Media",[191,192,193,194],"Paediatrics","Antibiotics","Digital Health","Infection","2025-09-17",{"date":197,"type":37},"2025-09-22",{"date":199,"type":37},"2025-09-16",{"date":201,"type":20},"2026-08",{"name":203,"class":44},"Murdoch Childrens Research Institute",{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":149,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":21,"phases":212,"briefSummary":215,"conditions":216,"keywords":217,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":169},"100557877","phase-1-st250-as-a-therapeutic-option-for-head--neck-reconstruction-100557877","NCT06543823","ST250 as a Therapeutic Option for Head & Neck Reconstruction","The Use of Suprathel®250 as a Novel Therapeutical Option for Mucosal Healing in Head and Neck Surgery","Inclusion Criteria:\n\n* recurrent episodes of tonsillar infection\n\nExclusion Criteria:\n\n* children\n* pregnant\u002F breastfeeding women\n* patients undergoing chemo \u002F radiotherapy",{"count":122,"type":20},[213,214],"PHASE1","PHASE2","To assess the use of SupraThel 250 for mucosal reconstruction in the Head \\& Neck region. The membrane will be applied after tonsillectomy procedures and compared to bare wounds' healing",[28],[218,219,220,99],"PLA membrane","Biodegradable membrane","Synthetic","2025-05-16",{"date":223,"type":37},"2025-05-18",{"date":225,"type":37},"2025-04-30",{"date":227,"type":20},"2026-02",{"name":229,"class":44},"Alaa Emara",{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":16,"minAge":238,"maxAge":4,"enrollmentInfo":239,"targetDuration":4,"studyType":21,"phases":241,"briefSummary":242,"conditions":243,"keywords":245,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":261},"100368907","phase-4-sore-throat-in-primary-care---a-comparison-of-phenoxymethylpenicillin-and-no-antibiotic-treatment-100368907","NCT04083417","Sore Throat in Primary Care - a Comparison of Phenoxymethylpenicillin and No Antibiotic Treatment","A Randomized Controlled Clinical Trial of Streptococcus Group A-negative Acute Tonsillitis in Primary Health Care - a Comparison of Phenoxymethylpenicillin and No Antibiotic Treatment","SANT","Inclusion Criteria:\n\n' Centor score 3-4: absence of cough, anamnestic fever (temperature \\>38.5°C), tender cervical lymphadenitis, and tonsillar exudates (one or both tonsils)\n\n* Duration of symptoms \\\u003C 8 days\n* Rapid antigen detection test for GAS taken and negative\n* Willing and able to give informed consent. Subjects under 18 years of age must in addition have the consent from both parents\u002Fcaretakers\n\nExclusion Criteria:\n\n* Ongoing antibiotic treatment\n* Known or suspected allergies to phenoxymethylpenicillin\n* Suspicion of peritonsillar abscess or indication for admittance.","15 Years",{"count":240,"type":20},260,[153],"Sore throat is the second most common cause of antibiotic prescribing in primary care in Sweden. Guidelines for sore throat focus on identifying people with sore throat where there are 3 and 4 specified criteria and where near patient tests identify group A streptococci (GAS). In these cases, phenoxymethylpenicillin is recommended.\n\nStudies that have identified microorganisms in sore throat show that there are other bacteria and viruses than GAS, that give similar symptoms and that sometimes no microorganism is trapped despite pronounced symptoms. In recent years, a bacterium F. necrophorum has been identified, which is found in increased incidence of sore throat, but it is also found in healthy individuals. In clinical practice, many patients are treated with penicillin even if GAS is not captured. This may be because the doctor perceives the patient as sick or because other bacteria are not caught with a near patient test which causes the doctor to treat anyway.\n\nThe specific aims are to in patients with GAS-negative sore throat and 3 and 4 criteria, aged 15 years and older in primary care, study whether phenoxymethylpenicillin treatment shortens the duration of the disease, reduces the symptom intensity and sickness absence, and investigates the importance of other microorganisms than GAS in sore throat.\n\nThe study is a randomized controlled trial in which patients with sore throat are randomized to phenoxymethylpenicillin 3 times daily for 10 days or to no antibiotic therapy. There will also be and a reference group with severe (Centor score 3-4), GAS-positive acute tonsillitis.\n\nBlood samples for inflammatory and immunological response to infections are taken. Throat samples for culture of F. necrophorum and streptococcal groups C and G, as well as polymerase chain reaction (PCR) analysis for bacteria and viruses are also taken at inclusion and at follow-up.\n\nThe outcome will be followed in a patient diary for 10 days and at a return visit after 18-24 days where the clinical outcome is asked for and where the blood- and throat samples are repeated.\n\nFollow-up will also takes place via e-mail after 1 and 3 months.",[244,28],"Sore Throat",[246,247,248,249,250],"sore throat","tonsillitis","randomized controlled trial","primary care","phenoxymethylpenicillin","2024-12-01",{"date":253,"type":37},"2024-12-04",{"date":255,"type":37},"2019-09-09",{"date":257,"type":20},"2026-06",{"name":259,"class":260},"Katarina Hedin","OTHER_GOV",6,{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":11,"sex":16,"minAge":269,"maxAge":86,"enrollmentInfo":270,"targetDuration":4,"studyType":21,"phases":272,"briefSummary":273,"conditions":274,"keywords":278,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":284,"leadSponsor":286,"locationsCount":4},"100552849","study-on-the-efficacy-and-safety-of-a-device-for-post-op-recovery-in-pediatric-adenectomyadenotonsillectomy-100552849","NCT06478433","Study on the Efficacy and Safety of a Device for Post-op Recovery in Pediatric Adenectomy\u002FAdenotonsillectomy.","\"Efficacy and Safety Study of the Medical Device Munatoril® Aerosol Combo in the Recovery of Nasal Homeostasis in Pediatric Patients Undergoing Adenoidectomy or Adenotonsillectomy.\"","Inclusion Criteria:\n\n* Patients of either sex aged 2 to 17 years who are candidates for adenoidectomy or adenotonsillectomy surgery.\n* Acquisition and signing of informed consent by the legal guardian.\n\nExclusion Criteria:\n\n* Syndromic patients.\n* Patients allergic to any substance in the study formulations.\n* Patients who have used intranasal corticosteroids, topical or systemic corticosteroids, or any intranasal medication in the week prior to study entry.\n* Active respiratory infection in the 2 weeks prior to study entry.\n* Patients with a history of chronic epistaxis or immunodeficiency.","2 Years",{"count":271,"type":20},90,[23],"The objective of this prospective pre-market interventional clinical study is to evaluate the efficacy and safety of the medical device Munatoril® Aerosol Combo in its different modalities of use, through the analysis of clinical and subjective outcomes in children operated on adenoidectomy or adenotonsillectomy, compared with a hypertonic solution and an over-the-counter isotonic solution (control group).\n\nThe primary question it aims to answer is whether the components prensent in Munatoril provide a benefit and whether they play a role in the recovery of nasal homeostasis following adeinodectomy and adenotonsillectomy compared with an over-the-counter hypertonic saline solution.\n\nEndpoints Evaluation of subjective longitudinal differences (intragroup over-time change) and differences between study group and control group (intergroup difference) regarding the use of the medical device, obtained following the protocol, with assessment at 8, 15 and 30 days after surgery by Likert Scale Score for tolerability, and at 0, 15 and 30 days by SNOT22 Score and Lund-Kennedy Endoscopic Score for efficacy.\n\nIn addition, there is a recording of any adverse events in both groups at 8, 15 and 30 days post-surgery, and an inter-group comparative evaluation.\n\nParticipants: Pediatric patients who are candidates for adenoidectomy or adenotonsillectomy surgery at the study site facility will be systematically evaluated preoperatively for inclusion in the clinical trial and possibly recruited. Follow-up will last 30 days.",[275,28,276,277],"Adenoidal Disorder","Otorhinolaryngologic Diseases","Nasal Disease",[279],"nasal irrigation","2024-07-02",{"date":282,"type":37},"2024-07-03",{"date":251,"type":20},{"date":285,"type":20},"2026-06-01",{"name":287,"class":288},"Pharmaluce srl","INDUSTRY",{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":149,"sex":16,"minAge":85,"maxAge":17,"enrollmentInfo":296,"targetDuration":4,"studyType":21,"phases":298,"briefSummary":299,"conditions":300,"keywords":301,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":169},"100333721","phase-4-gabapentin-premedication-to-reduce-postoperative-pain-for-pediatric-tonsillectomy-100333721","NCT03625011","Gabapentin Premedication to Reduce Postoperative Pain for Pediatric Tonsillectomy","Gabapentin Premedication to Reduce Postoperative Pain for Pediatric Tonsillectomy\u002FAdenoidectomy: Randomized Control Trial","Inclusion Criteria:\n\n* participants age 3-18 years\n* ASA class 1 or 2\n* elective Tonsillectomy\u002FAdenoidectomy\n* outpatient setting.\n\nExclusion Criteria:\n\n* BMI \\>40kg\u002Fm2\n* history of renal insufficiency, chronic pain\n* allergy to gabapentin\n* history of developmental delay",{"count":297,"type":20},50,[153],"The purpose of this pilot study: 1) to examine the use of gabapentin in reducing pain in the first 48 hours postoperatively including the total amount of narcotics mg\u002Fkg given 2) to record the time to first analgesic postoperatively and 3) to compare Wong Baker and the 0-10 numeric pain distress scale scores at 12, 24 and 48 hours postoperatively. We hypothesize one 15mg\u002Fkg (up to 600mg) dose of gabapentin will decrease mean narcotic amounts in mg\u002Fkg compared to participants who do not receive preoperative gabapentin and will demonstrate a decreased mean time to first analgesic as well as to lower mean pain scores for each age group at 12, 24 and 48 hours.",[28,99],[302,303],"Pain Relief","Non-Narcotic Pain relief","2019-07-23",{"date":306,"type":37},"2019-07-24",{"date":308,"type":37},"2018-07-31",{"date":310,"type":20},"2019-12-31",{"name":312,"class":44},"Children's Healthcare of Atlanta"]